RESUMO
ObjectiveChildren with Sickle Cell Disease (SCD), who are predominantly Black, face academic disparities in part because of the impact of longstanding racially biased education systems. Adverse systemic factors in addition to neurologic complications put children with SCD at risk for poor academic outcomes. Providing caregivers with information on how to select quality schools and advocate for their child's specific educational needs may influence academic outcomes and reduce educational disparities. We aimed to provide information to caregivers of children with SCD on school selection/quality, enrollment, and special education options.MethodsForty-six caregivers of children with SCD between the ages of 2 and 5:11 years participated in a structured informational session. Caregivers' sense of empowerment regarding educational options for their child was assessed via survey before and after the structured informational session.ResultsCaregivers reported feeling more informed and empowered following their participation in an informational session on school selection/quality, enrollment, and special education options for their child than before the informational session.ConclusionsIt is essential that families of children with SCD have the knowledge, skills, and sense of empowerment to access quality schools beginning in early childhood. Future research will determine if this intervention will improve children's access to academic support and academic outcomes. We theorize improvements in academic outcomes along with addressing systemic disparities may ultimately create a positive impact on vocational and quality of life outcomes in the lives of children with SCD.
Assuntos
Anemia Falciforme , Qualidade de Vida , Anemia Falciforme/complicações , Anemia Falciforme/terapia , Cuidadores , Criança , Pré-Escolar , Escolaridade , Humanos , Testes NeuropsicológicosRESUMO
Blastomyces is a fungus found in the soil of regions of North America including the Mississippi and Ohio River Valleys. It can be inhaled into the lungs and cause pneumonia and disseminated disease. Although blastomycosis is not widely reported in the sickle cell literature, sickle cell patients may be at increased risk of complications from blastomycosis pneumonia due to their immune compromise and risk of developing acute chest syndrome. We describe the case of a 13-year-old female with homozygous sickle cell disease who presented with pneumonia and acute chest syndrome and was found to have pulmonary blastomycosis.
Assuntos
Síndrome Torácica Aguda/patologia , Anemia Falciforme/fisiopatologia , Blastomyces/isolamento & purificação , Blastomicose/complicações , Pneumopatias Fúngicas/complicações , Pneumonia/complicações , Síndrome Torácica Aguda/etiologia , Adolescente , Blastomicose/microbiologia , Feminino , Humanos , Pneumopatias Fúngicas/microbiologia , Pneumonia/microbiologia , PrognósticoRESUMO
BACKGROUND: Although annual transcranial Doppler (TCD) screening is recommended for children with sickle cell anemia (SCA), compliance is low and variable. Our objective was to utilize an electronic health record (EHR)-based registry to improve TCD adherence among children with SCA, 2-16 years of age, at our institution. METHODS: We developed an in-EPIC real time registry for children with sickle cell disease in year 2016. Since end of year 2016, we have been extracting data quarterly to examine TCD rates and share the list of children who have not received a TCD screen in the past 18 months with the clinical team. The registry also includes a TCD risk score to enhance point of care. We also added Child Life support to increase TCD compliance among children <7 years. Control charts are used to examine TCD rates. RESULTS: At baseline, prior to and start of quarterly data audit and feedback, 63% of children received the recommended annual TCD screen. TCD rates steadily increased to 80% by the third quarter of 2017. We observed a dip in TCD rates, driven by failure of screening young children. Since the initiation of Child Life support for children <7 years, we have sustained TCD screen rates >70%. Overall, our data meet criteria for special cause variation, indicating improvement in TCD rates since 2015. CONCLUSIONS: Regular tracking and identification of patients overdue for a TCD screen using an EHR-based registry resulted in sustained improvement in TCD screening rates. Involvement of Child Life support further improved TCD rates.
Assuntos
Anemia Falciforme/diagnóstico por imagem , Anemia Falciforme/diagnóstico , Cooperação do Paciente/estatística & dados numéricos , Ultrassonografia Doppler Transcraniana/estatística & dados numéricos , Adolescente , Criança , Pré-Escolar , Humanos , Sistema de Registros/estatística & dados numéricosRESUMO
OBJECTIVE: To determine the association between health literacy, medication knowledge, and pain treatment skills with emergency department (ED) use of parents of children with sickle cell disease (SCD). METHODS: Parents of children 1- to 12-years-old with SCD were enrolled. Health literacy was assessed using the Newest Vital Sign. Parents completed a structured interview assessing knowledge of the dosage and frequency of home pain medications and an applied skills task requiring them to dose a prescribed pain medication. Underdosage was defined by too small a dose (dosage error) or too infrequent a dose (frequency error). The association between medication knowledge and applied skills with ED visits for pain over the past year was evaluated using Poisson regression adjusting for genotype. RESULTS: One hundred parent/child pairs were included; 50% of parents had low health literacy. Low health literacy was associated with more underdose frequency errors (38% vs. 19%, P = 0.02) on the skills task. On medication knowledge, underdose dosage errors (adjusted incidence rate ratio [aIRR] 2.0, 95% confidence interval [CI] 1.3-3.0) and underdose frequency errors (aIRR, 1.7, 95% CI 1.2-2.6) were associated with a higher rate of ED visits for pain. On the skills task, underdose dosage errors (aIRR 1.6, 95% CI 1.1-2-.4) and underdose frequency errors were associated with more ED visits (aIRR 1.5, 95% CI 1.1-2.1). CONCLUSIONS: For medication knowledge and skills tasks, children of parents who underdosed pain medication had a higher rate of ED visits for pain. Health literate strategies to improve parents' medication skills may improve pain treatment at home and decrease healthcare utilization.
Assuntos
Anemia Falciforme/tratamento farmacológico , Serviço Hospitalar de Emergência , Letramento em Saúde , Dor/tratamento farmacológico , Pais , Anemia Falciforme/complicações , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Dor/etiologiaRESUMO
BACKGROUND: Little is known about red blood cell (RBC) transfusion practices for children hospitalized for a sickle cell vaso-occlusive pain crisis (VOC). We hypothesized that transfusion would be associated with the development of acute chest syndrome (ACS), lower hemoglobin (Hb) concentration, and lack of hydroxyurea therapy. STUDY DESIGN AND METHODS: This is a secondary analysis of all children admitted for a sickle cell pain crisis enrolled in the Magnesium in Crisis (MAGiC) randomized trial; all had HbSS or S-ß0 thalassemia. ACS development and transfusion administration were prospectively collected during the parent trial. All Hb values during the hospitalization were recorded, as was parent report of child receiving hydroxyurea. Relative risks (RRs) of transfusion were compared between groups. RESULTS: Of 204 enrolled children, 40 (19.6%) received a transfusion. Of the 30 children who developed ACS, 22 (73.3%) received transfusions compared to 18 of 174 (10.3%) without ACS: the RR of transfusion in children with ACS was 7.1 (95% confidence interval [CI], 4.4-11.5). Among those without ACS, the lowest Hb was most strongly associated with transfusions: RR was 3.1 (95% CI 2.0 - 4.7) for each 1 g/dL decrease in lowest Hb. In a binary recursive partitioning model for those without ACS, a lowest recorded Hb level of less than 6.3 g/dL was significantly associated with transfusion during admission (p < 0.01). Hydroxyurea use was not associated with transfusions in any analysis. CONCLUSION: ACS increased the RR of transfusion in children hospitalized for VOC sevenfold. In children without ACS, transfusion was associated with lowest Hb concentration, particularly Hb concentration of less than 6.3 g/dL.
Assuntos
Anemia Falciforme/complicações , Arteriopatias Oclusivas/terapia , Transfusão de Eritrócitos , Síndrome Torácica Aguda/terapia , Adolescente , Anemia Falciforme/terapia , Arteriopatias Oclusivas/etiologia , Criança , Pré-Escolar , Hemoglobinas/análise , Humanos , Hidroxiureia/uso terapêutico , Adulto JovemRESUMO
Hemoglobin S/Black (A γδß)0 -thalassemia is a rare sickle cell disease (SCD) variant. On the basis of limited descriptions in the literature, the disease is reported as a mild microcytic anemia with an uncomplicated course. We report the clinical and laboratory data of nine patients whose diagnoses were confirmed by DNA-based techniques. Despite having mild anemia and high fetal hemoglobin level postinfancy, these patients developed many of the classic complications of SCD, including vaso-occlusive crisis, acute chest syndrome, avascular necrosis, and cholelithiasis. On the basis of these findings, we recommend that patients with this rare disorder receive specialized hematology care according to SCD guidelines.
Assuntos
Anemia Falciforme/patologia , Negro ou Afro-Americano/genética , Hemoglobina Fetal/genética , Hemoglobina Falciforme/genética , Talassemia/patologia , Adolescente , Adulto , Anemia Falciforme/genética , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Prognóstico , Índice de Gravidade de Doença , Talassemia/genética , Adulto JovemRESUMO
Neonates have low levels of antithrombin. Inadequate anticoagulation during cardiopulmonary bypass (CPB) due to low antithrombin activity may result in a poor preservation of the coagulation system during bypass. We hypothesize that antithrombin replacement to neonates prior to CPB will preserve the hemostatic system and result in less postoperative bleeding. A randomized, double-blinded, placebo-controlled pilot study of antithrombin replacement to neonates prior to CPB was conducted. Preoperative antithrombin levels determined the dose of recombinant antithrombin or placebo to be given. Antithrombin levels were measured following the dosing of the antithrombin/placebo, after initiation of bypass, near the completion of bypass, and upon intensive care unit admission. Eight subjects were enrolled. No subject had safety concerns. Mediastinal exploration occurred in two antithrombin subjects and one placebo subject. Antithrombin activity levels were significantly higher in the treated group following drug administration; levels continued to be higher than preoperatively but not different from the placebo group at all other time points. Total heparin administration was less in the antithrombin group; measurements of blood loss were similar in both groups. A single dose of recombinant antithrombin did not maintain 100% activity levels throughout the entire operation. Although no safety concerns were identified in this pilot study, a larger trial is necessary to determine clinical efficacy.
Assuntos
Anticoagulantes/administração & dosagem , Antitrombina III/administração & dosagem , Coagulação Sanguínea/efeitos dos fármacos , Ponte Cardiopulmonar , Cardiopatias Congênitas/cirurgia , Hemorragia Pós-Operatória/prevenção & controle , Anticoagulantes/efeitos adversos , Anticoagulantes/sangue , Antitrombina III/efeitos adversos , Testes de Coagulação Sanguínea , Ponte Cardiopulmonar/efeitos adversos , Método Duplo-Cego , Estudos de Viabilidade , Cardiopatias Congênitas/sangue , Cardiopatias Congênitas/diagnóstico , Heparina/administração & dosagem , Humanos , Recém-Nascido , Projetos Piloto , Hemorragia Pós-Operatória/sangue , Hemorragia Pós-Operatória/etiologia , Proteínas Recombinantes/administração & dosagem , Fatores de Tempo , Resultado do Tratamento , WisconsinRESUMO
PURPOSE: The purpose of this study was to define the hematologic response to total splenectomy (TS) or partial splenectomy (PS) in children with hereditary spherocytosis (HS) or sickle cell disease (SCD). METHODS: The Splenectomy in Congenital Hemolytic Anemia (SICHA) consortium registry collected hematologic outcomes of children with CHA undergoing TS or PS to 1 year after surgery. Using random effects mixed modeling, we evaluated the association of operative type with change in hemoglobin, reticulocyte counts, and bilirubin. We also compared laparoscopic to open splenectomy. RESULTS: The analysis included 130 children, with 62.3% (n=81) undergoing TS. For children with HS, all hematologic measures improved after TS, including a 4.1g/dl increase in hemoglobin. Hematologic parameters also improved after PS, although the response was less robust (hemoglobin increase 2.4 g/dl, p<0.001). For children with SCD, there was no change in hemoglobin. Laparoscopy was not associated with differences in hematologic outcomes compared to open. TS and laparoscopy were associated with shorter length of stay. CONCLUSION: Children with HS have an excellent hematologic response after TS or PS, although the hematologic response is more robust following TS. Children with SCD have smaller changes in their hematologic parameters. These data offer guidance to families and clinicians considering TS or PS.
Assuntos
Anemia Falciforme/sangue , Anemia Falciforme/cirurgia , Esferocitose Hereditária/sangue , Esferocitose Hereditária/cirurgia , Esplenectomia/métodos , Adolescente , Bilirrubina/sangue , Criança , Feminino , Hemoglobinas/metabolismo , Humanos , Laparoscopia , Masculino , Sistema de Registros , Contagem de ReticulócitosRESUMO
Magnesium, a vasodilator, anti-inflammatory, and pain reliever, could alter the pathophysiology of sickle cell pain crises. We hypothesized that intravenous magnesium would shorten length of stay, decrease opioid use, and improve health-related quality of life (HRQL) for pediatric patients hospitalized with sickle cell pain crises. The Magnesium for Children in Crisis (MAGiC) study was a randomized, double-blind, placebo-controlled trial of intravenous magnesium vs normal saline placebo conducted at 8 sites within the Pediatric Emergency Care Applied Research Network (PECARN). Children 4 to 21 years old with hemoglobin SS or Sß(0) thalassemia requiring hospitalization for pain were eligible. Children received 40 mg/kg of magnesium or placebo every 8 hours for up to 6 doses plus standard therapy. The primary outcome was length of stay in hours from the time of first study drug infusion, compared using a Van Elteren test. Secondary outcomes included opioid use and HRQL. Of 208 children enrolled, 204 received the study drug (101 magnesium, 103 placebo). Between-group demographics and prerandomization treatment were similar. The median interquartile range (IQR) length of stay was 56.0 (27.0-109.0) hours for magnesium vs 47.0 (24.0-99.0) hours for placebo (P = .24). Magnesium patients received 1.46 mg/kg morphine equivalents vs 1.28 mg/kg for placebo (P = .12). Changes in HRQL before discharge and 1 week after discharge were similar (P > .05 for all comparisons). The addition of intravenous magnesium did not shorten length of stay, reduce opioid use, or improve quality of life in children hospitalized for sickle cell pain crisis. This trial was registered at www.clinicaltrials.gov as #NCT01197417.
Assuntos
Anemia Falciforme/tratamento farmacológico , Magnésio/administração & dosagem , Dor/tratamento farmacológico , Vasodilatadores/administração & dosagem , Adolescente , Analgésicos Opioides/uso terapêutico , Anemia Falciforme/complicações , Criança , Pré-Escolar , Método Duplo-Cego , Feminino , Humanos , Infusões Intravenosas , Tempo de Internação , Masculino , Dor/etiologia , Qualidade de Vida , Adulto JovemRESUMO
The outcomes of children with congenital hemolytic anemia (CHA) undergoing total splenectomy (TS) or partial splenectomy (PS) remain unclear. In this study, we collected data from 100 children with CHA who underwent TS or PS from 2005 to 2013 at 16 sites in the Splenectomy in Congenital Hemolytic Anemia (SICHA) consortium using a patient registry. We analyzed demographics and baseline clinical status, operative details, and outcomes at 4, 24, and 52 weeks after surgery. Results were summarized as hematologic outcomes, short-term adverse events (AEs) (≤30 days after surgery), and long-term AEs (31-365 days after surgery). For children with hereditary spherocytosis, after surgery there was an increase in hemoglobin (baseline 10.1 ± 1.8 g/dl, 52 week 12.8 ± 1.6 g/dl; mean ± SD), decrease in reticulocyte and bilirubin as well as control of symptoms. Children with sickle cell disease had control of clinical symptoms after surgery, but had no change in hematologic parameters. There was an 11% rate of short-term AEs and 11% rate of long-term AEs. As we accumulate more subjects and longer follow-up, use of a patient registry should enhance our capacity for clinical trials and engage all stakeholders in the decision-making process.
Assuntos
Síndrome Torácica Aguda/patologia , Anemia Hemolítica Congênita/cirurgia , Anemia Falciforme/cirurgia , Anquirinas/deficiência , Complicações Pós-Operatórias/patologia , Infecções Respiratórias/patologia , Esferocitose Hereditária/cirurgia , Esplenectomia/métodos , Síndrome Torácica Aguda/etiologia , Adolescente , Anemia Hemolítica Congênita/patologia , Anemia Falciforme/patologia , Bilirrubina/sangue , Criança , Pré-Escolar , Feminino , Hemoglobinas/metabolismo , Humanos , Masculino , Sistema de Registros , Infecções Respiratórias/etiologia , Reticulócitos/patologia , Esferocitose Hereditária/patologia , Resultado do Tratamento , Estados UnidosRESUMO
Multiple recent Sickle Cell Disease studies have been terminated due to poor enrollment. We developed methods to overcome past barriers and utilized these to study the efficacy and safety of intravenous magnesium for vaso-occlusive crisis (VOC). We describe the methods of the Intravenous Magnesium in Sickle Vaso-occlusive Crisis (MAGiC) trial and discuss methods used to overcome past barriers. MAGiC was a multi-center randomized double-blind placebo-controlled trial of intravenous magnesium versus normal saline for treatment of VOC. The study was a collaboration between Pediatric Hematologists and Emergency Physicians in the Pediatric Emergency Care Applied Research Network (PECARN). Eligible patients were randomized within 12 hours of receiving intravenous opioids in the Emergency Department (ED) and administered study medication every 8 hours. The primary outcome was hospital length of stay. Associated plasma studies elucidated magnesium's mechanism of action and the pathophysiology of VOC. Health-related quality of life was measured. Site-, protocol-, and patient-related barriers from prior studies were identified and addressed. Limited study staff availability, lack of collaboration with the ED, and difficulty obtaining consent were previously identified barriers. Leveraging PECARN resources, forging close collaborations between Sickle Cell Centers and EDs of participating sites, and approaching eligible patients for prior consent helped overcome these barriers. Participation in the PECARN network and establishment of collaborative arrangements between Sickle Cell Centers and their affiliated EDs are major innovative features of the MAGiC study that allowed improved subject capture. These methods could serve as a model for future studies of VOCs.
Assuntos
Anemia Falciforme/complicações , Arteriopatias Oclusivas/tratamento farmacológico , Comunicação Interdisciplinar , Sulfato de Magnésio/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto/métodos , Vasodilatadores/uso terapêutico , Anemia Falciforme/sangue , Anti-Inflamatórios/efeitos adversos , Anti-Inflamatórios/farmacologia , Arteriopatias Oclusivas/sangue , Arteriopatias Oclusivas/etiologia , Biomarcadores/sangue , Comportamento Cooperativo , Citocinas/sangue , Serviço Hospitalar de Emergência/organização & administração , Hospitais Pediátricos/organização & administração , Hospitais Especializados/organização & administração , Humanos , Hipotensão/induzido quimicamente , Consentimento Livre e Esclarecido , Infusões Intravenosas , Relações Interprofissionais , Tempo de Internação/estatística & dados numéricos , Sulfato de Magnésio/efeitos adversos , Sulfato de Magnésio/farmacologia , Entorpecentes/uso terapêutico , Dor/tratamento farmacológico , Dor/etiologia , Qualidade de Vida , Vasodilatadores/efeitos adversos , Vasodilatadores/farmacologiaRESUMO
A female infant with unbalanced right ventricular dominant atrioventricular septal defect with double-outlet right ventricle and pulmonary stenosis had recurrent aortopulmonary shunt thrombosis. She was found to have low antithrombin levels and was managed with antithrombin replacement in addition to unfractionated heparin. A subsequent aortopulmonary shunt was successfully placed, and patency was maintained. Her antithrombin levels normalized, and she was continued on low-molecular-weight heparin and aspirin until four months of age when a bidirectional superior cavopulmonary anastomosis was done. A prothrombotic evaluation at the time of the acute thrombosis and repeated at four months of age was negative except for the initially low antithrombin level. A repeat antithrombin level (off supplementation) at the time of the cavopulmonary anastomosis was normal making the diagnosis of congenital antithrombin deficiency unlikely. This case highlights the possibility of neonatal antithrombin deficiency as a cause of aortopulmonary shunt thrombosis and successful management with replacement therapy.
Assuntos
Anormalidades Múltiplas/cirurgia , Antitrombinas/sangue , Dupla Via de Saída do Ventrículo Direito/cirurgia , Derivação Cardíaca Direita , Defeitos dos Septos Cardíacos/cirurgia , Estenose da Valva Pulmonar/cirurgia , Trombose/diagnóstico , Trombose/tratamento farmacológico , Anormalidades Múltiplas/diagnóstico , Anticoagulantes/uso terapêutico , Biomarcadores/sangue , Dupla Via de Saída do Ventrículo Direito/complicações , Dupla Via de Saída do Ventrículo Direito/diagnóstico , Feminino , Derivação Cardíaca Direita/métodos , Defeitos dos Septos Cardíacos/complicações , Defeitos dos Septos Cardíacos/diagnóstico , Humanos , Recém-Nascido de Baixo Peso , Recém-Nascido , Estenose da Valva Pulmonar/complicações , Estenose da Valva Pulmonar/diagnóstico , Prevenção Secundária , Trombose/sangue , Trombose/etiologia , Resultado do Tratamento , Ultrassonografia Pré-NatalRESUMO
Vitamin B12 deficiency is rare in children, with nonspecific symptoms including failure to thrive, vomiting, anorexia, and neurologic changes with or without hematologic disturbances. The neuropathy can be severe and irreversible. We report four cases of children with B12 deficiency secondary to adult type pernicious anemia, a presumed transport protein abnormality, and a metabolic defect. All demonstrated neurologic compromise that improved after initiation of B12 therapy. Hematologic manifestations may be preceded by constitutional, gastrointestinal, or neurologic changes, and must raise concern for B12 deficiency. Therapy should be initiated promptly in this setting to prevent irreversible neuropathy.
Assuntos
Anemia Perniciosa/complicações , Insuficiência de Crescimento/etiologia , Deficiência de Vitamina B 12/etiologia , Vitamina B 12/uso terapêutico , Adolescente , Adulto , Pré-Escolar , Insuficiência de Crescimento/diagnóstico , Insuficiência de Crescimento/tratamento farmacológico , Feminino , Humanos , Masculino , Prognóstico , Deficiência de Vitamina B 12/diagnóstico , Deficiência de Vitamina B 12/tratamento farmacológicoRESUMO
To compare the non-neurological events in children with sickle cell anemia (SCA) and previous stroke enrolled in SWiTCH. The NHLBI-sponsored Phase III multicenter randomized clinical trial stroke with transfusions changing to hydroxyurea (SWiTCH) (ClinicalTrials.gov NCT00122980) compared continuation of chronic blood transfusion/iron chelation to switching to hydroxyurea/phlebotomy for secondary stroke prevention and management of iron overload. All randomized children were included in the analysis (intention to treat). The Fisher's Exact test was used to compare the frequency of subjects who experienced at least one SCA-related adverse event (AE) or serious adverse event (SAE) in each arm and to compare event rates. One hundred and thirty three subjects, mean age 13 ± 3.9 years (range 5.2-19.0 years) and mean time of 7 years on chronic transfusion at study entry, were randomized and treated. Numbers of subjects experiencing non-neurological AEs were similar in the two treatment arms, including SCA-related events, SCA pain events, and low rates of acute chest syndrome and infection. However, fewer children continuing transfusion/chelation experienced SAEs (P = 0.012), SCA-related SAEs (P = 0.003), and SCA pain SAEs (P = 0.016) as compared to children on the hydroxyurea/phlebotomy arm. The timing of phlebotomy did not influence SAEs. Older age at baseline predicted having at least 1 SCA pain event. Patients with recurrent neurological events during SWiTCH were not more likely to experience pain. In children with SCA and prior stroke, monthly transfusions and daily iron chelation provided superior protection against acute vaso-occlusive pain SAEs when compared to hydroxyurea and monthly phlebotomy.
Assuntos
Anemia Falciforme/terapia , Antidrepanocíticos/efeitos adversos , Terapia por Quelação/efeitos adversos , Sobrecarga de Ferro/prevenção & controle , Flebotomia/efeitos adversos , Acidente Vascular Cerebral/prevenção & controle , Reação Transfusional , Síndrome Torácica Aguda/epidemiologia , Síndrome Torácica Aguda/etiologia , Síndrome Torácica Aguda/prevenção & controle , Adolescente , Adulto , Anemia Falciforme/tratamento farmacológico , Anemia Falciforme/fisiopatologia , Antidrepanocíticos/uso terapêutico , Benzoatos/efeitos adversos , Benzoatos/uso terapêutico , Criança , Pré-Escolar , Estudos de Coortes , Deferasirox , Feminino , Humanos , Hidroxiureia/efeitos adversos , Hidroxiureia/uso terapêutico , Incidência , Quelantes de Ferro/efeitos adversos , Quelantes de Ferro/uso terapêutico , Sobrecarga de Ferro/etiologia , Sobrecarga de Ferro/fisiopatologia , Masculino , Medição da Dor , Prevenção Secundária , Acidente Vascular Cerebral/etiologia , Triazóis/efeitos adversos , Triazóis/uso terapêutico , Adulto JovemRESUMO
BACKGROUND: Children with sickle cell disease (SCD) demonstrate deficits in cognitive and academic functioning. This study compared the academic attainment of children with SCD relative to national, state, and local school district rates for African American students. METHODS: A retrospective chart review of children with SCD was completed and academic information was collected from caregiver report and school records. One-sample tests of proportions were calculated to compare academic attainment rates in children with SCD relative to national, state, and local school district normative data of African American students. RESULTS: Overall, 197 patient records were reviewed. A higher proportion of children with SCD were retained a grade relative to national, state, and local school district rates for African American students. In addition, a higher proportion of children with SCD received special education services relative to the national, state, and local school district rates for African American students. CONCLUSION: Children with SCD demonstrate higher rates of special education services and grade retention relative to African American peers. Overall, children with SCD demonstrate poorer academic attainment relative to healthy, African American peers highlighting the need for increased focus on special education services to address school performance issues within this population.
Assuntos
Anemia Falciforme/psicologia , Escolaridade , Absenteísmo , Negro ou Afro-Americano/psicologia , Negro ou Afro-Americano/estatística & dados numéricos , Criança , Feminino , Humanos , Masculino , Estudos Retrospectivos , Estados Unidos/epidemiologiaRESUMO
Although rare, passive transfer of platelet antibodies through blood products can result in thrombocytopenia, acute transfusion reactions, and death. We report a case of severe alloimmune thrombocytopenia from a plasma transfusion. A postliver transplant patient with a normal platelet count received fresh frozen plasma before liver biopsy. Postbiopsy, she developed cardiorespiratory distress, petechiae, and severe thrombocytopenia (platelet count 2000/µL). Her platelet count recovered to normal after 1 week. This diagnosis should be considered whenever an unexpected drop in the platelet count occurs after a plasma-rich transfusion. Conservative transfusion practices and more targeted donor screening may prevent similar events.
Assuntos
Transfusão de Componentes Sanguíneos/efeitos adversos , Isoanticorpos/imunologia , Plasma/imunologia , Trombocitopenia/imunologia , Antígenos de Plaquetas Humanas/imunologia , Pré-Escolar , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Isoanticorpos/efeitos adversos , Transplante de FígadoRESUMO
BACKGROUND: Stroke occurs in 5-10% of children with sickle cell anemia (SCA) and has a high (>50%) risk of recurrence without therapy. Chronic monthly erythrocyte transfusions effectively prevent recurrent stroke, but their long-term use is limited by serious side effects, including iron overload. An alternative to transfusion for secondary stroke prevention in SCA is needed, especially one that also improves the management of iron overload. METHODS: Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) is an NHLBI-sponsored Phase III multicenter randomized controlled clinical trial for children with SCA, stroke, and iron overload (NCT00122980). The primary goal of SWiTCH is to compare 30 months of alternative therapy (hydroxyurea and phlebotomy) with standard therapy (transfusions and chelation) for the prevention of secondary stroke and reduction of transfusional iron overload. DISCUSSION: SWiTCH has several distinctive study features including novel methodological and design components: (1) composite primary endpoint including both stroke recurrence rate and iron burden; (2) non-inferiority design with an "acceptable" increased stroke risk; (3) transfusion goals based on current academic community practices; (4) special oversight for the enrollment and randomization process; (5) overlap treatment period within the alternative treatment arm; (6) masking of the overall trial Principal Investigator to treatment results; (7) inclusive independent stroke adjudication process for all suspected new neurological events; and (8) periodic therapeutic phlebotomy program to alleviate iron overload. CONCLUSION: Investigation of alternative treatments in SWiTCH could lead to changes in the management of cerebrovascular disease for selected patients with SCA, stroke, and iron overload.
Assuntos
Anemia Falciforme/terapia , Transfusão de Eritrócitos , Hidroxiureia/uso terapêutico , Sobrecarga de Ferro/terapia , Acidente Vascular Cerebral/terapia , Adolescente , Adulto , Anemia Falciforme/complicações , Terapia por Quelação , Criança , Pré-Escolar , Transfusão de Eritrócitos/efeitos adversos , Humanos , Sobrecarga de Ferro/etiologia , Sobrecarga de Ferro/prevenção & controle , Acidente Vascular Cerebral/etiologia , Acidente Vascular Cerebral/prevenção & controle , Adulto JovemRESUMO
BACKGROUND/PURPOSE: Partial splenectomy has emerged as a surgical option for selected children with hereditary spherocytosis, with the goal of reducing anemia while preserving splenic function. This multi-institutional study is the largest series to date examining outcomes data for partial splenectomy in patients with hereditary spherocytosis. METHODS: Data were collected retrospectively from 5 North American pediatric hospitals. Sixty-two children underwent partial splenectomy for hereditary spherocytosis between 1990 and 2008. RESULTS: At 1 year following partial splenectomy, mean hemoglobin significantly increased by 3.0 ± 1.4 g/dL (n = 52), reticulocyte count decreased by 6.6% ± 6.6% (n = 41), and bilirubin level decreased by 1.3 ± 0.9 mg/dL (n = 25). Patients with poor or transient hematologic response were found to have significantly more splenic regeneration postoperatively compared with patients with a durable clinical response (maximal spleen dimension, 9.0 ± 3.4 vs 6.3 ± 2.2 cm). Clinically significant recurrence of anemia or abdominal pain led to completion splenectomy in 4.84% of patients. No patients developed postsplenectomy sepsis. CONCLUSIONS: Our multi-institutional review indicates that partial splenectomy for hereditary spherocytosis leads to sustained and clinically significant improvement in hematologic profiles and clinical symptoms in most patients. Our data support partial splenectomy as an alternative for selected children with hereditary spherocytosis.
Assuntos
Esferocitose Hereditária/cirurgia , Esplenectomia/métodos , Adolescente , Bilirrubina/sangue , Criança , Pré-Escolar , Feminino , Seguimentos , Hospitais Pediátricos/estatística & dados numéricos , Humanos , Lactente , Masculino , Regeneração/fisiologia , Contagem de Reticulócitos/estatística & dados numéricos , Esferocitose Hereditária/sangue , Baço/fisiologia , Resultado do TratamentoAssuntos
Anemia Falciforme/tratamento farmacológico , Antidrepanocíticos/uso terapêutico , Hidroxiureia/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto , Adolescente , Fatores Etários , Antidrepanocíticos/efeitos adversos , Criança , Pré-Escolar , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Humanos , Hidroxiureia/efeitos adversos , Projetos de PesquisaRESUMO
We conducted a prospective, multicenter investigation of human-leukocyte antigen (HLA) identical sibling bone marrow transplantation (BMT) in children with severe sickle cell disease (SCD) between 1991 and 2000. To determine if children were protected from complications of SCD after successful BMT, we extended our initial study of BMT for SCD to conduct assessments of the central nervous system (CNS) and of pulmonary function 2 or more years after transplantation. In addition, the impact on gonadal function was studied. After BMT, patients with stroke who had stable engraftment of donor cells experienced no subsequent stroke events after BMT, and brain magnetic resonance imaging (MRI) exams demonstrated stable or improved appearance. However, 2 patients with graft rejection had a second stroke after BMT. After transplantation, most patients also had unchanged or improved pulmonary function. Among the 11 patients who had restrictive lung changes at baseline, 5 were improved and 6 had persistent restrictive disease after BMT. Of the 2 patients who had obstructive changes at baseline, 1 improved and 1 had worsened obstructive disease after BMT. There was, however, significant gonadal toxicity after BMT, particularly among female recipients. In summary, individuals who had stable donor engraftment did not experience sickle-related complications after BMT, and were protected from progressive CNS and pulmonary disease.